Key result
LAAO fails to reduce composite major events versus DOACs despite lower mortality.
Why the study?
The comparative effectiveness and safety of LAAO versus contemporary OAC, particularly DOACs, for stroke prevention in atrial fibrillation remain uncertain.
Does left atrial appendage occlusion reduce the composite of ischemic stroke, major bleeding, systemic embolism, all-cause mortality, and cardiovascular mortality compared with oral anticoagulation (particularly DOACs) in patients with atrial fibrillation?
Meta-Analysis (n=106,947)
Does left atrial appendage occlusion reduce the composite of ischemic stroke, major bleeding, systemic embolism, all-cause mortality, and cardiovascular mortality compared with oral anticoagulation (particularly DOACs) in patients with atrial fibrillation?
Answers are grounded in this paper and cite their sources.
In this large meta-analysis of 106,947 atrial fibrillation patients, LAAO showed no significant difference in the primary composite outcome, ischemic stroke, or major bleeding compared with DOACs, but was associated with lower all-cause and cardiovascular mortality.
Left atrial appendage occlusion (LAAO) has emerged as an alternative to oral anticoagulation (OAC) for stroke prevention in patients with atrial fibrillation. However, the comparative effectiveness and safety of LAAO versus contemporary OAC, particularly direct oral anticoagulants (DOACs), remain uncertain. We performed an updated systematic review and meta-analysis comparing LAAO with OAC, incorporating both vitamin K antagonist– and DOAC-based studies, with prespecified subgroup analyses of DOAC-treated populations and an exploratory analysis in patients with chronic kidney disease. We included 26 studies (6 randomized controlled trials and 20 observational studies) comprising 106,947 participants, with a mean age of 74.2 years. Follow-up ranged from 3 months to 5 years. Compared with DOACs, LAAO was not associated with a statistically significant difference in the primary composite outcome of ischemic stroke, major bleeding, systemic embolism, all-cause mortality, and cardiovascular mortality (hazard ratio 0.71, 95% confidence interval 0.47–1.07; P = 0.09; I 2 = 80%). No significant differences were observed in ischemic stroke or major bleeding compared with overall OAC or DOAC therapy. LAAO was nevertheless associated with significantly lower risks of all-cause and cardiovascular mortality compared with both overall OAC and DOAC therapy.
No takes yet. Share an insight, caveat, or question.
Sebastian et al. (2026) conducted a meta-analysis in Atrial fibrillation (n=106,947). Left atrial appendage occlusion (LAAO) vs. Oral anticoagulation (OAC), including vitamin K antagonists and direct oral anticoagulants (DOACs) was evaluated on Primary composite outcome of ischemic stroke, major bleeding, systemic embolism, all-cause mortality, and cardiovascular mortality (compared with DOACs) (HR 0.71, 95% CI 0.47-1.07, p=0.09). Left atrial appendage occlusion did not reduce the primary composite outcome versus DOACs, though all-cause and cardiovascular mortality were lower.
Synapse has enriched 10 related papers. Consider them for comparative context: